Summit Therapeutics launches a Phase 2 trial of ivonescimab-based treatments for advanced kidney cancer, targeting enrollment ...

Perfect Corp shareholders approve its $2-per-share merger with ProjectNY, with 99.99% of votes cast in favor of the proposed ...

JPMorgan Chase & Co. deployed $230 billion of capital, providing equity and debt financing across a handful of areas, ...

Ardagh agrees to sell its 42% Trivium Packaging stake in a $3.4 billion deal involving Silgan, expecting $90 million in net ...

EyePoint plans a 53% workforce reduction after its LUCIA trial misses its primary endpoint, targeting $30 million in annual ...

Merck agrees to acquire Silence Therapeutics for $20 per ADS in a $1.3 billion equity deal, adding Divesiran to its rare ...

Chord Energy reports Q3 2026 production of 290,500–290,900 barrels daily, $205 million in share repurchases and a $550 ...

Mako Mining recovers 12,743 ounces of gold in Q3 2026, generating $50 million in revenue while advancing Moss, Mt. Hamilton ...

AST SpaceMobile supports four European telecom operators exploring a satellite spectrum bid, targeting connectivity ...

Cleveland-Cliffs reports $612 million in Q3 2026 adjusted EBITDA, $5.6 billion revenue and forecasts over $4 billion in ...

Brent crude falls 2.08% to $107.57 as Trump waives Russia sanctions, while WTI drops to $99.46 amid continuing Middle East ...

AbbVie reports 40.5% endoscopic remission with ABBV-466 at Week 24 in its Phase 2a Crohn's disease trial, compared with 22.4% ...